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Effect of the Ginger Derivative, 6-Shogaol, on Ferritin Levels in Patients
With Low to Intermediate-1-Risk Myelodysplastic Syndrome-A Small,
Investigative Study
Abstract

Background: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders
characterized by dysplastic and ineffective hematopoiesis and peripheral cytopenias. Elevated serum ferritin
(SF) is often observed in nontransfused, lower risk MDS. It has been reported that ineffective erythropoiesis
enhances iron absorption in MDS through downregulation of hepcidin and its prohormones such that SF
rises. Aim: To determine the effect of 6-shogaol, a dehydration derivative of ginger, known to have
hepatoprotective and chemotherapeutic activity, on 6 early-stage, transfusion-independent patients with
MDS, 3 of whom had raised levels of SF. Method: Six patients with MDS with low or intermediate-1 subtypes,
as defined by the International Prognostic Scoring System (IPSS), were recruited into the study and were
administered 1 gel capsule daily containing 20 mg ginger extract standardized for 20% 6-shogaol. Blood and
urine samples were collected and various markers monitored at regular intervals. Results: 6-shogaol caused a
decrease in SF levels in 3 of 6 patients with early MDS (50%) whose SF levels were elevated at the start of the
study. Our findings suggest upregulation of hepcidin and its prohormones, possibly through an improvement
in liver function. Discussion: In light of the encouraging results in this small, investigative study, we are
planning a larger study to confirm the beneficial effect of 6-shogaol in patients with raised ferritin levels due to
ineffective erythropoiesis.
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ABSTRACT
Background: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders characterized by dysplastic and
ineffective hematopoiesis and peripheral cytopenias. Elevated serum ferritin (SF) is often observed in nontransfused, lower risk MDS. It has
been reported that ineffective erythropoiesis enhances iron absorption in MDS through downregulation of hepcidin and its prohormones
such that SF rises.
Aim: To determine the effect of 6-shogaol, a dehydration derivative of ginger, known to have hepatoprotective and chemotherapeutic activity, on 6 early-stage, transfusion-independent patients with MDS, 3 of whom had raised levels of SF.
Method: Six patients with MDS with low or intermediate-1 subtypes, as defined by the International Prognostic Scoring System (IPSS), were
recruited into the study and were administered 1 gel capsule daily containing 20 mg ginger extract standardized for 20% 6-shogaol. Blood
and urine samples were collected and various markers monitored at regular intervals.
Results: 6-shogaol caused a decrease in SF levels in 3 of 6 patients with early MDS (50%) whose SF levels were elevated at the start of
the study. Our findings suggest upregulation of hepcidin and its prohormones, possibly through an improvement in liver function.
Discussion: In light of the encouraging results in this small, investigative study, we are planning a larger study to confirm the beneficial
effect of 6-shogaol in patients with raised ferritin levels due to ineffective erythropoiesis.
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Introduction

Myelodysplastic syndrome (MDS) is a heterogeneous group of
clonal stem cell disorders characterized by dysplastic and ineffective hematopoiesis and peripheral cytopenias. The natural
history of MDS is variable, ranging from the indolent condition spanning years, to a form rapidly progressing to acute
myelogenous leukemia.1 The disease predominates in an
elderly population, the median age being approximately
70 years. Many of these patients also have numerous comorbid
conditions which make the use of natural compounds, with little or no toxicity, highly desirable in the lower risk MDS,
defined by the International Prognostic Scoring System (IPSS)
as low or intermediate-1 (Int-1) subtypes.
Elevated serum ferritin (SF) is often observed in nontransfused, patients with lower risk MDS. Kikuchi et al2 evaluated baseline SF levels in nontransfused patients with MDS
and found that the SF level was significantly higher in
patients with MDS compared with healthy controls. They
also found that the SF level of patients with higher risk MDS
was significantly higher than that of the patients with lower
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risk MDS. These authors suggest that baseline SF level may
be an independent prognostic factor for overall survival and
leukemia-free survival (LFS) in patients with MDS as the
LFS was significantly shorter in the high SF group than in
the low SF group. High SF at diagnosis (>500 ng/mL) was
significantly associated with future development of transfusion dependency.
The liver polypeptide hepcidin plays a pivotal role in iron
homeostasis. In macrophages, it accelerates the degradation of
the transmembrane iron exporter ferroportin messenger RNA.
In intestinal epithelial cells, it is believed to downregulate divalent metal transporter 1, which is involved in the transfer of
iron across the intestinal wall.3 It has been reported that ineffective erythropoiesis enhances iron absorption in MDS
through downregulation of hepcidin and its prohormones such
that SF rises.4
Plants of the ginger family have been credited with
hepatoprotective activity.5,6 The substance called [6]-gingerol is the main active compound in ginger root and the

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial
4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

one that gives ginger its distinctive flavor. Shogaols are the
dehydration products of gingerols during storage or thermal processing. Hepatoprotective effects of 6-shogaol have
been found in animal studies against ethanol, carbon tetrachloride, diclofenac, and acetaminophen-induced hepatotoxicity. Zhuang et al6 identified that shogaol in
ginger-derived nanoparticles specifically targets hepatocytes and plays a role in the induction of nuclear factor
erythroid 2–related factor 2 (Nrf2). Nrf2 transcriptionally
controls the gene expression of many cytoprotective
enzymes and plays an important role in protecting liver
against insults. A study by Alquasoumi et al5 showed that
pretreatment of rats with 6-shogaol for 6 days exhibited a
significant protective effect on diclofenac sodium-induced
hepatic injury by reduction in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
phosphatase compared with controls. Their results showed
that 6-shogaol prevented diclofenac sodium (DFS)-induced
acute hepatotoxicity by protecting serum marker enzymes,
bilirubin, and antioxidant activity.
Based on the above findings, we have conducted a small,
investigative study to evaluate the effect of 6-shogaol in 6 early
stages, transfusion-independent patients with MDS, 3 of
whom had raised levels of SF.

Methods

Six patients with low or Int-1–risk MDS, as defined by the
IPSS, were recruited into the study. The study was performed
in the Department of Endocrinology at St George Hospital,
Sydney, and informed consent was obtained from each patient
before recruitment. Patients were administered 1 gel capsule
daily containing 20 mg ginger extract standardized for 20%
6-shogaol. Blood samples were drawn at baseline and at
2-monthly intervals for a period of 6 months (initial study—i).
Based on the decrease in SF levels shown in 3 of 6 patients
with elevated SF and the improvement in liver function markers shown in 1 patient, the study was repeated on 2 of 3 patients
for a further 6 months (repeat study—r) with a washout period
of 3 months between the initial study and the repeat study.
Markers monitored for the initial study (i) included full blood
count, serum chemistry, liver function, reticulocyte count,
Coombs test, and serum iron studies. Markers monitored for
the repeat study (r) included full blood count, serum chemistry,
liver function, and the add-on tests for 24-hour urine iron
excretion and serum hepcidin levels.
Hepcidin was measured in serum using a highly precise
and validated liquid chromatography method, incorporating online extraction and coupled with tandem mass
spectrometry.7

Results

There were 4 men and 2 women with an average age of
70 years in the study (Table 1). The mean disease duration
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was 5.6 years. Of the 6 patients, 5 patients (83%) completed
the 6-month initial study. One patient (no. 5) stopped the
initial study at month 4 and was lost to follow-up. Two
patients, due to their decrease in SF levels (nos 1 and 3) in the
initial study, were entered into the repeat study with a washout period of 3 months, and both these patients completed
the 6-month repeat study, ie, a total of 12 months shogaol
therapy. None of the patients were treated with anything
other than the 6-shogaol during the study period and none
displayed ill effects from the 6-shogaol.
In the study, 4 of 6 (67%) patients were anemic at baseline
and all had variable cytopenias (Table 1). There was no change
in cell counts over the course of the initial or repeat study
period.
Of the 6 patients, 3 (50%—nos 1, 3, 5) had elevated SF
levels at baseline (Table 1). No sign of infection or inflammation was found in any of these patients. Patient no. 1 had a
high alcohol intake which may have also contributed to his
significantly high SF. All 3 patients showed a >40% decrease
in SF by the end of the initial study period (Table 1). Patients
1 and 3 repeated the study, with a 3-month washout period
between the initial study and the repeat study. In patient 1, the
decreased SF remained stable during the 3 month washout
period. Once shogaol therapy was recommenced, SF continued to decrease from baseline by the end of the repeat study
(51% decrease from baseline in initial study and 58% decrease
from baseline by the end of the repeat study; Figure 1). Urinary
iron excretion was measured in the 2 patients participating in
the repeat study and there was no effect of the 6-shogaol on
urinary iron excretion.
In addition to significantly elevated SF at baseline
(2195 μg/L—normal: 30-300 μg/L), patient no. 1 had significantly elevated liver function enzymes (γ-glutamyl transferase [GGT], ALT, and AST) at baseline which was most
likely associated with his high alcohol intake and he did not
decrease his alcohol intake (his intake remained constant
during the year that he participated in both the initial and
the repeat studies). All 3 liver function enzymes (GGT, ALT,
and AST) decreased during the 12 months on shogaol therapy with ALT and AST falling (53% and 40%, respectively)
to within normal range (Table 2). The decrease in SF and
liver function enzymes seen in patient no. 1 was accompanied by an increase in serum hepcidin in the repeat study
(12.3-19.3 ng/mL—an increase in 57% from the start to the
end of the repeat study; Table 2).
Table 2 shows the decrease in SF levels and liver function
enzymes in patient no. 1 over both the initial study period (i)
and the repeat study period (r) (SF decreased by 58% from initial baseline, GGT decreased by 19% from initial baseline, ALT
decreased by 53% from initial baseline, AST decreased by 40%
from initial baseline). Serum hepcidin levels were measured in
the repeat study, and the table shows a 57% increase from
repeat baseline.
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Table 1. Hematologic parameters, WHO type, and iron studies of the 6 early patients with MDS at the start of the initial study (SOS) and the end of
the initial study (EOS).
Patient
no.

Age/
sex

WHOtype
MDS

1

54/M

RCMD

2

3

4

5

6

64/M

72/M

72/F

85/M

75/F

RCMD

RCMD

CMML-1

RCMD

RARS

Hb (128175 g/L)

WCC (411 × 109/L)

Neut. (27.5 × 109/L)

Pltlts (150450 × 109/L)

SOS

151

3.6

1.76

29

EOS

151

4.1

2.43

SOS

95

5.1

EOS

93

SOS

Retic.
(20100 × 109)

Iron (530 µmol/L)

TIBC
(46-70
µmol/L)

Ferritin
(30300 µg/L)

%
saturation
(10%-45%)

95

28

56

2195

50

38

93

35.9

58

1071

62

2.31

214

24

28

37

222

76

4.6

2.1

195

22

24

58

275

58

108

2.9

1.48

114

76

22.4

50

709

45

EOS

101

1.7

0.67

94

61

29.4

48

387

61

SOS

152

6.8

1.2

133

38

21.8

NA

94

36

EOS

137

9.5

2.7

148

52

10.5

NA

122

19

SOS

94

6.5

3.27

193

165

10.7

48

336

22

EOS

125

4.5

2.05

79

122

16.8

56

117

30

SOS

91

5.4

2.61

467

32

29.5

44

198

67

EOS

88

5

2.18

464

34

35.7

44

227

81

Abbreviations: EOS, end of study; Hb, hemoglobin; neut., neutrophils; pltlts, platelets; RARS, refractory anemia with ringed sideroblast; RCC, red cell count; RCMD,
refractory cytopenia with multilineage dysplasia; retic., reticulocytes; SOS, start of study; TIBC, total iron-binding capacity; WCC, white cell count; WHO, World Health
Organization.

Discussion

Figure 1. Serum ferritin (SF) levels of patient no. 1 during the initial (i)
study, washout period and the repeat (r) study. The decrease in SF levels
in patient no. 1 over 6-month period of initial study, stabilization during
the washout period, and further decrease over 6-month repeat study
period. Patient no. 1 showed a 58% decrease in SF levels from initial
baseline.

Patient no. 3 had a 45% decrease in SF from baseline to
6 months in the initial study (709-387 μg/L). During the
3-month washout period, his SF levels increased (to 664 μg/L).
Reintroduction of shogaol once again led to a decrease in SF (to
390 μg/L; Figure 2). This decrease in SF remained at 45% from
baseline in the repeat study. The decrease in SF was accompanied by an increase in serum hepcidin in the repeat study (19 ng/
mL at start of repeat study to 42.2 ng/mL at end of repeat
study). Liver function enzymes in this patient were within normal range during both the initial and repeat studies.

The patients with lower risk MDS, whose disease is monitored
on a “watch and wait” basis, represent the ideal conditions to
test the role of nontoxic natural compounds. The rationale for
using 6-shogaol in this small, investigative study is that both
the ginger-derived 6-gingerol and 6-shogaol show anticarcinogenic, hepatoprotective, and anti-inflammatory activities.8–10
6-Shogaol has been found to have much stronger growth
inhibitory effects than 6-gingerol on H1299 human lung cancer cells and HCT-116 human colon cancer cells.11
Although the 6-shogaol had no effect on cell counts, the
results of our study show that 6-shogaol caused a decrease
in SF levels in 3 of 6 patients with early MDS (50%) whose
SF levels were elevated at the start of the study.
The decrease in SF level was reproduced in repeat studies
in 2 patients. Neither had changed his dietary habits and
urinary iron excretion remained normal during the study
periods. The decrease in SF was accompanied by an increase
in serum hepcidin level in both patients. A decrease in elevated liver function enzymes was seen in patient 1 with a
history of excess alcohol consumption, in keeping with probable hepatoprotective activity of 6-shogaol.5,6
Our findings suggest upregulation of hepcidin and its prohormones, with the resultant decrease in SF level attributable
to decreased absorption of dietary iron. The improvement in
liver function in patient 1 may reflect less cellular damage, as
has been shown in animal studies by Zhuang and Alqasoumi.5,6
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Table 2. Patient no. 1—SF and liver function enzyme values during the initial (i) and repeat (r) study (ie, 12-month study period) and hepcidin levels
in repeat study.
Bsl. (i)

M2 (i)

M4 (i)

M6 (i)

Bsl (r)

M2

M4 (r)

M6 (r)

% ch. fr. bsl.

2195

2017

1537

1071

1057

935

967

929

−58

GGT (5-50 U/L)

151

132

132

137

117

116

110

123

−19

ALT (5-40 U/L)

80

81

59

43

54

49

39

38

−53

AST (10-40 U/L)

70

73

51

48

48

47

37

42

−40

Iron (5-30 μmol/L)

28

17.6

35.7

35.9

39.8

25.5

43.4

27.9

0

TIBC (46-70 μmol/L)

56

58

54

58

60

56

54

56

0

% srn (10%-45%)

50

30

66

62

66

46

80

50

0

12.3

16.8

8.3

19.3

57

Ferritin (30-300 μg/L)

Hepcidin (16-288 ng/mL)

Abbreviations: % ch. fr. bsl., percentage change from baseline; % srn, percentage saturation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; bsl.,
baseline; GGT, γ-glutamyl transferase; TIBC, total iron-binding capacity.

AM: recruited patients, consulted on study methodology, monitored follow-up visits, assisted with analysis of results and
study write-up.
RR: recruited study patients, monitored follow-up visits.
VB: provided study concept and product.
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